NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00400907,Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9,https://clinicaltrials.gov/study/NCT00400907,,UNKNOWN,"RATIONALE: Treatment for diffuse large B-cell non-Hodgkin's lymphoma may cause side effects and secondary cancers later in life. An observational study that evaluates patients after undergoing six courses of combination chemotherapy with or without rituximab and radiation therapy may help doctors predict a patient's response to this treatment and help plan the best treatment.

PURPOSE: This observational study is evaluating patients with diffuse large B-cell non-Hodgkin's lymphoma to see how well treatment on clinical trial CAN-NCIC-LY9 works.",NO,Long-term Effects Secondary to Cancer Therapy in Adults|Lymphoma,OTHER: clinical observation|PROCEDURE: management of therapy complications,Time to treatment failure,"Complete remission rate|Relapse rate|Overall survival|Tumor control|Disease-free survival|Time to progression|Time to relapse|Late toxicities, particularly organ function deficiencies (e.g., cardiomyopathies), infections, and secondary neoplasms",,German High-Grade Non-Hodgkin's Lymphoma Study Group,,ALL,ADULT,,667,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,CDR0000514350|DSHNHL-MINT-FU|EU-20656|DSHNHL-M39045,2006-01,,,2006-11-17,,2011-12-20,,
